LITERATURE REVIEW OF ORAL TREATMENT OF TYPE 2 DIABETES MELLITUS

  • Mousa SHA’AT “Grigore T. Popa” University of Medicine and Pharmacy Iasi
  • Cristina Mihaela GHICIUC “Grigore T. Popa” University of Medicine and Pharmacy Iasi
  • Alexandra BUJOR “Grigore T. Popa” University of Medicine and Pharmacy Iasi
  • D. V. TIMOFTE “Grigore T. Popa” University of Medicine and Pharmacy Iasi
  • Alina ȘTEFANACHE “Grigore T. Popa” University of Medicine and Pharmacy Iasi
  • Lăcrămioara OCHIUZ “Grigore T. Popa” University of Medicine and Pharmacy Iasi

Abstract

Type 2 non-insulin-dependent diabetes mellitus (T2DM), the most common form of diabetes that affects more than 90% of diabetic patients, is characterized by insulin resistance, β-pancreatic cells dysfunction, and increased hepatic glucose synthesis. The aim of the present paper was to review data on the efficacy of conventional oral dosage forms compared to controlled oral drug delivery systems for treating diabetes. Although the number of oral antidiabetic drugs has significantly increased in recent years, clinically there are still important limitations in terms of therapeutic efficacy, tolerability, and adverse effects, particularly regarding weight gain and medium and long-term glucose control. The last generation of oral pharmaceutical formulations such as modified-release tablets overcame some limitations, while injectable formulations with glucagon-like peptide-1 receptor agonists significantly increased the effectiveness of anti-diabetic medication and significantly reduced diabetes-specific comorbidities. Metformin extended-release formulation seems to be more effective than metformin conventional-release formulation in improving glyco-metabolic control, lipid profile, and levels of some adipocytokines in T2DM. Sustained-release glipizide formulation increases the compliance compared to immediate-release glipizide because it seems to achieve similar glucose control with decreased insulin secretion and to decrease the frequency of hypoglycemic episodes. Gliclazide modified release formulation seems to be effective and safe in T2DM with suboptimal glycemic control. Modified release formulations generate other advantages such as increasing treatment compliance, lowering the dose of drug substance, and even reducing side effects.

Author Biographies

Mousa SHA’AT, “Grigore T. Popa” University of Medicine and Pharmacy Iasi

Faculty of Pharmacy

Cristina Mihaela GHICIUC, “Grigore T. Popa” University of Medicine and Pharmacy Iasi

Faculty of Medicine

Alexandra BUJOR, “Grigore T. Popa” University of Medicine and Pharmacy Iasi

Faculty of Pharmacy

D. V. TIMOFTE, “Grigore T. Popa” University of Medicine and Pharmacy Iasi

Faculty of Medicine

Alina ȘTEFANACHE, “Grigore T. Popa” University of Medicine and Pharmacy Iasi

Faculty of Pharmacy

Lăcrămioara OCHIUZ, “Grigore T. Popa” University of Medicine and Pharmacy Iasi

Faculty of Pharmacy

References

1. Adak T, Samadi A, Ünal AZ, Sabuncuoğlu S. A reappraisal on metformin. Regul Toxicol Pharmacol 2018; 92: 324-332.
2. *** World Health Organization. Classification of diabetes mellitus. Geneva: World Health Organiza-tion; 2019. Licence: CC BY-NC-SA 3.0 IGO. ISBN 978-92-4-151570-2.
3. Md. Akil H, Rokeya P. Current Antidiabetic Drug: Review of Their Efficacy and Safety. Nutritional and Therapeutic Interventions for Diabetes and Metabolic Syndrome (2nd edition), London, UK, Aca-demic Press, 2018.
4. ***World Health Organization. Global Report on Diabetes (https://apps.who.int/iris/ bitstream/handle/ 10665/204871/9789241565257_eng.pdf.
5. https://www.diabetesatlas.org/upload/resources/2019/IDF_Atlas_9th_Edition_2019.pdf.
6. Mota M, Popa SG, Mota E, et al. Prevalence of diabetes mellitus and prediabetes in the adult Romanian population: PREDATORR study. J Diabetes 2016; 8(3): 336-344.
7. Brietzke SA, Oral antihyperglycemic treatment options for type 2 diabetes mellitus, Med. Clin. N. Am 2015; 99(1): 87-106.
8. Romero R, Erez O, Hüttemann M, Maymon E, Panaitescu B, Conde-Agudelo A, Pacora P, Yoon BH, Grossman LI. Metformin, the aspirin of the 21st century: its role in gestational diabetes mellitus, pre-vention of preeclampsia and cancer, and the promotion of longevity. Am J Obstet Gynecol 2017; 217: 282-302.
9. Verdonck LF, Sangster B, van Heijst ANP et al. Buformin concentrations in a case of fatal lactic acidosis. Diabetologia 1981; 20: 45-46.
10. ***U.S. National Library of Medicine (National Center for Biotechnology Information) - https://pubchem.ncbi.nlm.nih.gov/.
11. Mehnert H. Metformin, the rebirth of a biguanide: mechanism of action and place in the prevention and treatment of insulin resistance. Exp Clin Endocrinol Diabetes 2001; 109(Suppl 2): S259-264.
12. Bailey CJ. Biguanides and NIDDM. Diabetes Care 1992; 15: 755-772.
13. Graham R, Ewan R.P., Kei Sakamoto. Molecular mechanism of action of metformin: old or new insights? Diabetologia 2013; 56: 1898-1906.
14. Ji L, Liu J, Yang J, et al. Comparative effectiveness of metformin monotherapy in extended release and immediate release formulations for the treatment of type 2 diabetes in treatment-naïve Chinese patients: analysis of results from the CONSENT trial. Diabetes Obes Metab 2018; 20: 1006-1013.
15. Derosa G, D'Angelo A, Romano D, Maffioli P. Effects of metformin extended release compared to immediate release formula on glycemic control and glycemic variability in patients with type 2 diabe-tes. Drug Des Devel Ther 2017; 11: 1481-1488.
16. *** Nomenclatorul medicamentelor pentru uz uman (ANMDMR - Agenția Națională a Medicamentului și a Dispozitivelor Medicale din România) https://www.anm.ro/nomenclator/medicamente.
17. Tran L, Zielinski A, Roach AH, Jende JA, Householder AM, Cole EE, et al Pharmacologic treatment of type 2 diabetes: oral medications. Ann Pharmacother 2015; 49(5): 540-556.
18. *** American Diabetes Association. Pharmacologic approaches to glycemic treatment: standards of medical care in diabetes - 2019. Diabetes Care 2019; 42(Suppl 1): S90-S102
19. Ahad A, Al-Saleh AA, Akhtar N, Al-Mohizea AM, Al-Jenoobi FI. Transdermal delivery of antidia-betic drugs: formulation and delivery strategies. Drug Discovery Today 2015; 20: 1217-1227.
20. Chaudhury A, Duvoor C, Reddy Dendi VS, et al. Clinical Review of Antidiabetic Drugs: Implications for Type 2 Diabetes Mellitus Management. Front Endocrinol (Lausanne) 2017; 8: 6.
21. Li Wang, Xin Sun, Liang Du, Qiang Yuan, et al. Effects and Patient Compliance of Sustained-Release Versus Immediate-Release Glipizides in Patients With Type 2 Diabetes Mellitus: A Systematic Review and Meta-Analysis. J Evid Based Med. 2011; 4(4): 232-241.
22. Leiter LA, Shestakova MV, Trubitsyna NP, Piletič M, Satman I. Implementing an Optimized Glucose-Lowering Strategy With a Novel Once Daily Modified Release Gliclazide Formulation. Diabetes Res Clin Pract 2016; 112: 50-56.
23. Nissen SE, Wolski K. Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. N Engl J Med 2007; 356(24): 2457-2471.
24. Jang JY, Bae H, Lee YJ, et al. Structural Basis for the Enhanced Anti-Diabetic Efficacy of Lobeglita-zone on PPARγ. Sci Rep 2018; 8(1): 31.
25. Dabhi AS, Bhatt NR, Shah MJ. Voglibose: an alpha glucosidase inhibitor. J Clin Diagn Res 2013; 7(12): 3023-3027.
26. Koh N, Sakamoto S, Chino F. Improvement in medication compliance and glycemic control with voglibose oral disintegrating tablet. Tohoku J Exp Med 2008; 216: 249-257.
27. Nishio S, Abe M, Ito H. Anagliptin in the treatment of type 2 diabetes: safety, efficacy, and patient acceptability. Diabetes Metab Syndr Obes 2015; 8: 163-171.
28. Sharma SK, Panneerselvam A, Singh KP, Parmar G, Gadge P, Swami OC. Teneligliptin in manage-ment of type 2 diabetes mellitus. Diabetes Metab Syndr Obes 2016; 9: 251-60.
29. McCormack PL. Evogliptin. First global approval. Drugs 2015; 75(17): 2045-2049.
30. Iskandar Idris, Richard Donnelly. Sodium-glucose co-transporter-2 inhibitors: an emerging new class of oral antidiabetic drug. Diabetes Obes Metab 2009; 11: 79-88.
31. Paik J, Blair HA. Dapagliflozin: A Review in Type 1 Diabetes Drugs 2019; 79(17): 1877-1884.
32. Chawla G, Chaudhary KK. A complete review of empagliflozin: Most specific and potent SGLT2 inhibitor used for the treatment of type 2 diabetes mellitus. Diabetes Metab Syndr 2019; 13(3): 2001-2008.
Published
2020-09-30